ReviewJournal of clinical medicine2021
Circulating Biomarkers of Colorectal Cancer (CRC)-Their Utility in Diagnosis and Prognosis.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Metabolomic Profiling Identified Serum Metabolite Biomarkers and Related Metabolic Pathways of Colorectal Cancer.Disease markers · 2021Trial
- Evaluation of a research use only (RUO) TIMP-1 assay for use with the automated AlinityBiochemistry and biophysics reports · 2026Article
- Individual chemotherapy for patients colorectal cancer based on patient-derived tumor-like cell clusters.World journal of gastrointestinal surgery · 2026Article
- Bioinformatics combined with machine learning for the identification of malignant transformation markers in colorectal polyps.Frontiers in molecular biosciences · 2026Article
- Aptamer-Based Strategies for Colorectal Cancer Detection: Emerging Technologies and Future Directions.Biosensors · 2025Review
- Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer.Biochemical genetics · 2025Article
- Targeting inflammasomes as an immunotherapeutic strategy for cancer.Journal of translational medicine · 2025Review
- Multiclassification of Colorectal Polyps from Colonoscopy Images Using AI for Early Diagnosis.Diagnostics (Basel, Switzerland) · 2025Article
- Associations of serum and tissue TIMP1 with host response and survival in colorectal cancer.Scientific reports · 2025Article
- Regulation of Metastasis and Growth of Colorectal CancerRecent patents on anti-cancer drug discovery · 2025Article
- Recent Updates on Protease Zymography.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Increased amounts of cell-free DNA released from a culture with a high content of cancer stem cells.Frontiers in cell and developmental biology · 2025Article
- Article
- The survival prediction of advanced colorectal cancer received neoadjuvant therapy-a study of SEER database.World journal of surgical oncology · 2024Article
- Serum IGFBP-1 as a promising diagnostic and prognostic biomarker for colorectal cancer.Scientific reports · 2024Article
- Investigation of the expression level of methylated septin 9 gene and serological carcinoembryonic antigen to diagnose colorectal cancer. A meta-analysis study.Przeglad gastroenterologiczny · 2024Review
- Comparative analysis of matrix metalloproteinases by zymography in patients with colorectal carcinoma.Physiological research · 2023Article
- Serum concentrations of proinflammatory biomarker interleukin-6 (IL-6) as a predictor of postoperative complications after elective colorectal surgery.World journal of surgical oncology · 2023Article
- Non-Genomic Hallmarks of Aging-The Review.International journal of molecular sciences · 2023Review
- Integrated analysis of single-cell and bulk RNA-seq establishes a novel signature for prediction in gastric cancer.World journal of gastrointestinal oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The global burden of colorectal cancer (CRC) is expected to increase, with 2.2 million new cases and 1.1 million annual deaths by 2030. Therefore, the establishment of novel biomarkers useful in the early diagnosis of CRC is of utmost importance. A number of publications have documented the significance of the overexpression of several specific proteins, such as inflammatory mediators, in CRC progression. However, little is known about the potential utility of these proteins as circulating blood tumor biomarkers of CRC. Therefore, in the present review we report the results of our previous original studies as well as the findings of other authors who investigated whether inflammatory mediators might be used as novel biomarkers in the diagnosis and prognosis of CRC. Our study revealed that among all of the tested proteins, serum M-CSF, CXCL-8, IL-6 and TIMP-1 have the greatest value in the diagnosis and progression of CRC. Serum TIMP-1 is useful in differentiating between CRC and colorectal adenomas, whereas M-CSF and CRP are independent prognostic factors for the survival of patients with CRC. This review confirms the promising significance of these proteins as circulating biomarkers for CRC. However, due to their non-specific nature, further validation of their sensitivity and specificity is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.